Advertisement

Task Force Report on Obstetric Antiphospholipid Syndrome

  • D. Ware Branch
  • Benjamin Leader
  • Carl A. Laskin
Chapter

Abstract

The obstetric criteria for antiphospholipid syndrome (APS) were first formalized in 1999 at the 10th International Congress on Antiphospholipid Antibodies (aPL). In 2010, the Organizing Committee for the upcoming 13th International Congress on aPL formed an Obstetric APS Task Force. The intent was to kindle discussion regarding obstetric APS prior to the meeting and then to engender participation among interested experts and attendees at a half-day Task Force meeting to be held the day before the official start of the Congress. The Task Force concluded that there is virtually no evidence from properly designed trials to guide clinicians with regard to prevention of fetal death, severe preeclampsia, or placental insufficiency attributed to APS. Also, no clear consensus was reached with regard to resolving discrepancies in existing trials of heparin treatment for recurrent early miscarriage attributed to APS. A majority of Task Force members were in agreement that studies in the field of APS must be carefully planned with regard to such critical elements as case and control matching and inclusion and exclusion criteria. Moreover, the ability to perform repeat testing and confirmatory testing in a central laboratory would be mandatory.

Keywords

Task Force Fetal Death Lupus Anticoagulant Severe Preeclampsia Postpartum Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

In addition to the authors, the Task Force Members for Obstetric APS were the following: Alijotas-Reig, Jaume, MD, PhD (Vall d’Hebron University Hospital, Universitat Autònoma, Barcelona, Spain), Alba, Paula, MD, PhD (Universidad Nacional de Cordoba, Cordoba, Argentina), Buyon, Jill, MD (Hospital for Joint Diseases, New York, NY), Cohen, Hannah, MD (University College London Hospitals, London, UK), Contreras, Juan A. MD, de Jesus, Guilherme MD (Universidade do Estado do Rio de Janeiro, Brazil), de Jesus, Nilson Ramires MD (Universidade do Estado do Rio de Janeiro, Brazil), Farran-Codina, Inma, MD, PhD, Grand, Beatriz, MD (University of Buenos Aires, Buenos Aires, Argentina), Greco, Thomas P., MD (Saint Mary’s Hospital, Waterbury, CT), Harraca, Monica G., MD, Kutteh, Billy, MD, PhD (University of Tennessee, Memphis, TN), Levy, Roger A., MD, PhD (Universidade do Estado do Rio de Janeiro, Brazil), Lockshin, Michael, MD (Hospital for Special Surgery, New York, NY), Makatsariya, Alexander, MD, PhD, Maria-Otero, Ana, MD, Michelon, Tatiana, MD, PhD, Pappalardo, Cecilia, MD (Halitus Medical Institute, Buenos Aires, Argentina), Parke, Ann, MD (University of Connecticut Health Center, Farmington, CT), Pierangeli, Silvia,PhD (University of Texas Medical Branch, Galveston, TX), Ruiz, Itziar Garcia, MD, Salmon, Jane, MD (Hospital for Special Surgery, New York, NY), Sarto, Adriana, MD (Halitus Medical Institute, Buenos Aires, Argentina), Silver, Robert, MD (University of Utah Health Sciences Center, Salt Lake City, UT), Zarzoso, Cristina, MD (Vall d’Hebron University Hospital, Universitat Autònoma, Barcelona, Spain).

References

  1. 1.
    Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.PubMedCrossRefGoogle Scholar
  2. 2.
    Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.PubMedCrossRefGoogle Scholar
  3. 3.
    Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J. 1997;314:253–7.CrossRefGoogle Scholar
  5. 5.
    Clifford K, Rai R, Watson H, Regan L. Pregnancy: an informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod. 1994;9:1328–32.PubMedGoogle Scholar
  6. 6.
    Branch DW, Silver RM, Porter TF. Obstetric antiphospholipid syndrome: current uncertainties should guide our way. Lupus. 2010;19:446–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Bruce IN, Clark-Soloninka CA, Spitzer KA, Gladman DD, Urowitz MB, Laskin CA. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol. 2000;27:2833–7.PubMedGoogle Scholar
  8. 8.
    Chauleur C, Galanaud JP, Alonso S, et al. Ovservational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Throm Haemost. 2010;8:699–706.CrossRefGoogle Scholar
  9. 9.
    Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100:408–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Laskin CA, Spitzer K, Clark C, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol. 2009;36:279–87.PubMedCrossRefGoogle Scholar
  11. 11.
    Kaandorp SP, Goddijn M, van der Post JAM, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Eng J Med. 2010;362:1586–96.CrossRefGoogle Scholar
  12. 12.
    Clark P, Walker ID, Langhorne P, et al. SPIN: the Scottish pregnancy intervention study: a multicentre randomized trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood. 2010;115:4162–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80:614–20.PubMedGoogle Scholar
  14. 14.
    Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep. 2007;9:219–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Dreyfus M, Hedelin G, Kutnahorsky R, et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstet Gynecol. 2001;97:29–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Branch DW, Porter TF, Rittenhouse L, et al. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet. 2001;184:825–32.CrossRefGoogle Scholar
  17. 17.
    Pattison NS, Chamley LW, McKay EJ, et al. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol. 1993;100:909–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Inten Med. 1994;120:470–5.CrossRefGoogle Scholar
  20. 20.
    Katano K, Aoki A, Sasa H, et al. Beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod. 1996;11:509–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Faden D, Tincani A, Tanzi P, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Eur J Obstet Gynecol Reprod Biol. 1997;73:37–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Yamada H, Atsumi T, Amengual O, et al. Glycoprotein-I antibody increases the risk of pregnancy-induced hypertension: a case-controlled study. J Reprod Immunol. 2010;84:95–9. epub ahead of print.PubMedCrossRefGoogle Scholar
  23. 23.
    Nodler J, Moolamalla SR, Ledger SM, et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth. 2009;9:11–8.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:844–66.CrossRefGoogle Scholar
  25. 25.
    Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long term aspirin use and mortality in women. Arch Int Med. 2007;167:562–72.CrossRefGoogle Scholar
  26. 26.
    Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7:58–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • D. Ware Branch
    • 1
  • Benjamin Leader
    • 2
  • Carl A. Laskin
    • 3
  1. 1.Department of Obstetrics & GynecologyUniversity of Utah HospitalSalt Lake CityUSA
  2. 2.Department of Clinical ResearchReproSource, Inc.WoburnUSA
  3. 3.Department of Medicine, Obstetrics & Gynecology and ImmunologyUniversity of TorontoTorontoCanada

Personalised recommendations